share_log

歌禮製藥-B：授出購股權

ASCLETIS-B: GRANT OF SHARE OPTIONS

香港交易所 ·  Jan 3 04:30
Summary by Moomoo AI
歌禮製藥有限公司於2024年1月3日向39名參與者授出總計6,300,000份購股權，該購股權計劃於2019年6月6日採納。其中，執行董事、董事會主席、行政總裁及主要股東吳勁梓博士及執行董事、高級副總裁及主要股東何淨島女士各被授予1,000,000份購股權。購股權的行使價為每股1.448港元，有效期為十年，且無附帶任何表現目標。購股權的歸屬期分五階段，從2025年至2029年逐年歸屬。所有購股權均受購股權計劃的回撥機制規限，且本集團不會提供任何財務資助促成購股權計劃。該授權已獲獨立非執行董事批准。
歌禮製藥有限公司於2024年1月3日向39名參與者授出總計6,300,000份購股權，該購股權計劃於2019年6月6日採納。其中，執行董事、董事會主席、行政總裁及主要股東吳勁梓博士及執行董事、高級副總裁及主要股東何淨島女士各被授予1,000,000份購股權。購股權的行使價為每股1.448港元，有效期為十年，且無附帶任何表現目標。購股權的歸屬期分五階段，從2025年至2029年逐年歸屬。所有購股權均受購股權計劃的回撥機制規限，且本集團不會提供任何財務資助促成購股權計劃。該授權已獲獨立非執行董事批准。
Song Pharmaceuticals Limited granted a total of 6,300,000 share options to 39 participants on 3 January 2024. The share option plan was adopted on 6 June 2019. Among them, the Executive Director, Chairman of the Board, Chief Executive Officer and Major Shareholder Dr. Wu Jinzi and Executive Director, Senior Vice President and Major Shareholder Ms. Ho Jingshima were each granted 1,000,000 share options. The exercise price of the share option is HK$1.448 per share for a period of 10 years and is not accompanied by any performance targets. The vesting period of the share rights will be divided in five phases, from 2025 to 2029 on an annual basis. ALL SHARE OPTIONS ARE SUBJECT TO THE REVOCATION MECHANISM OF THE SHARE OPTION SCHEME AND THE GROUP WILL NOT PROVIDE ANY FINANCIAL SUPPORT TO FACILITATE THE SHARE OPTION SCHEME. The license has been approved by an independent non-executive director.
Song Pharmaceuticals Limited granted a total of 6,300,000 share options to 39 participants on 3 January 2024. The share option plan was adopted on 6 June 2019. Among them, the Executive Director, Chairman of the Board, Chief Executive Officer and Major Shareholder Dr. Wu Jinzi and Executive Director, Senior Vice President and Major Shareholder Ms. Ho Jingshima were each granted 1,000,000 share options. The exercise price of the share option is HK$1.448 per share for a period of 10 years and is not accompanied by any performance targets. The vesting period of the share rights will be divided in five phases, from 2025 to 2029 on an annual basis. ALL SHARE OPTIONS ARE SUBJECT TO THE REVOCATION MECHANISM OF THE SHARE OPTION SCHEME AND THE GROUP WILL NOT PROVIDE ANY FINANCIAL SUPPORT TO FACILITATE THE SHARE OPTION SCHEME. The license has been approved by an independent non-executive director.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more